Significance and strategies in developing delivery systems for bio-macromolecular drugs

Abstract

Successful development of a new drug is prohibitively expensive, and is estimated to cost approximately $100–500 million US dollars for a single clinical drug. Yet, a newly developed drug can only enjoy its patent protection for 18 years, meaning that after this protected time period, any company can manufacture this product and thus the profit generated by this drug entity would reduce dramatically. Most critically, once a drug is being synthesized, its physical, chemical, and biological attributes such as bioavailability and in vivo pharmacokinetics are all completely fixed and cannot be changed. In principal and practice, only the application of an appropriately designed drug delivery system (DDS) is able to overcome such limitations, and yet the cost of developing a novel drug delivery system is less than 10% of that of developing a new drug. Because of these reasons, the new trend in pharmaceutical development has already begun to shift from the single direction of developing new drugs in the past to a combined mode of developing both new drugs and innovative drug delivery systems in this century. Hence, for developing countries with relatively limited financial resources, a smart strategic move would be to focus on the development of new DDS, which has a significantly higher benefit/risk ratio when comparing to the development of a new drug.

Because of the unmatched reaction efficiency and a repetitive action mode, the therapeutic activity of a single bio-macromolecular drug (e.g., protein toxins, gene products, etc.) is equivalent to about 10⁶–10⁸ of that from a conventional small molecule anti-cancer agent (e.g., doxorubicin). Hence, bio-macromolecular drugs have been recognized around the world as the future “drug-of-choice”. Yet, among the>10000 drugs that are currently available, only ~150 of them belong to these bio-macromolecular drugs (an exceedingly low 1.2%), reflecting the difficulties of utilizing these agents in clinical practice. In general, the bottleneck limitations of these bio-macromolecular drugs are two-fold: (1) the absence of a preferential action of the drug on tumor cells as opposed to normal tissues, and (2) the lack of ability to cross the tumor cell membrane. In this review, we provide strategies of how to solve these problems simultaneously and collectively via the development of innovative drug delivery systems. Since worldwide progress on bio-macromolecular therapeutics still remains in the infant stage and thus open for an equal-ground competition, we wish that this review would echo the desire to industrialized countries such as China to set up its strategic plan on developing delivery systems for these bio-macromolecular drugs, thereby realizing their clinical potential.

Keywords

delivery systems / bio-macromolecular drugs / cell penetrating peptides

References

[1] Allen T M, Cullis P R. Drug delivery systems: entering the mainstream. Science, 2004, 303(5665): 1818–1822

[2] Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews, 2002, 54(5): 631–651

[3] Dreher M R, Liu W, Michelich C R, Dewhirst M W, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. Journal of the National Cancer Institute, 2006, 98(5): 335–344

[4] Maeda H, Seymour L W, Miyamoto Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjugate Chemistry, 2002, 3(5): 351–362

[5] Takakura Y, Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Critical Reviews in Oncology/Hematology, 1995, 18(3): 207–231

[6] Defoort J P, Nardelli B, Huang W, Ho D D, Tam J P. Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89(9): 3879–3883

[7] Hamajima K, Bukawa H, Fukushima J, Kawamoto S, Kaneko T, Sekigawa K I, Tanaka S I, Tsukuda M, Okuda K. A macromolecular multicomponent peptide vaccine prepared using the glutaraldehyde conjugation method with strong immunogenicity for HIV-1. Clinical Immunology and Immunopathology, 1995, 77(3): 374–379

[8] Greenberg S, Frishman W. Co-enzyme Q10: A new drug for cardiovascular disease. The Journal of Clinical Pharmacology, 1990, 30(7): 596–608

[9] Torchilin V P. Targeting of drugs and drug carriers within the cardiovascular system. Advanced Drug Delivery Reviews, 1995, 17(1): 75–101

[10] Chang C-T L, Liou H-Y, Tang H L, Sung H Y. Activation, purification and properties of beta-amylase from sweet potatoes (Ipomoea batatas). Biotechnology and Applied Biochemistry, 1996, 24: 13–18

[11] Noda T, Furuta S, Suda I. Sweet potato [beta]-amylase immobilized on chitosan beads and its application in the semi-continuous production of maltose. Carbohydrate Polymers, 2001, 44(3): 189–195

[12] Thorpe P E, Burrows F J. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Research and Treatment, 1995, 36(2): 237–251

[13] Bandres E, Andion E, Escalada A, Honorato B, Catalan V, Cubedo E, Cordeu L, Garcia F, Zarate R, Zabalegui N, Garcia-Foncillas J. Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. Journal of Neuro-Oncology, 2005, 73(3): 189–198

[14] Buchner J, Pastan I, Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies. Analytical Biochemistry, 1992, 205(2): 263–270

[15] Chen C, Ridzon D A, Broomer A J, Zhou Z, Lee D H, Nguyen J T, Barbisin M, Xu N L, Mahuvakar V R, Andersen M R, Lao K Q, Livak K J, Guegler K J. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Research, 2005, 33(20): e179

[16] Gibson U E, Heid C A, Williams P M. A novel method for real time quantitative RT-PCR. Genome Research, 1996, 6(10): 995–1001

[17] Siebert P D, Chenchik A, Kellogg D E, Lukyanov K A, Lukyanov S A. An improved PCR method for walking in uncloned genomic DNA. Nucleic Acids Research, 1995, 23(6): 1087–1088

[18] Syrigos K N, Epenetos A A. Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations. Anticancer Research, 1999, 19(1A): 605–613

[19] Bagshawe K D. Antibody directed enzymes revive anti-cancer prodrugs concept. British Journal of Cancer, 1987, 56(5): 531–532

[20] Liang J F, Li Y T, Song H, Park Y J, Naik S S, Yang V C. ATTEMPTS: A heparin/protamine-based delivery system for enzyme drugs. Journal of Controlled Release, 2002, 78(1–3): 67–79

[21] Doxorubicin Hydrochloride. In: AHFS Drug Information, American Hospital Formulary Service, Bethesda, MD. 2001, 950–960

[22] Liang J F, Park Y J, Song H, Li Y T, Yang V C. ATTEMPTS: A heparin/protamine-based prodrug approach for delivery of thrombolytic drugs. Journal of Controlled Release, 2001, 72(1–3): 145–156

[23] Foldvari M, Mezei C, Mezei M. Intracellular delivery of drugs by liposomes containing P₀ glycoprotein from peripheral nerve myelin into human M21 melanoma cells. Journal of Pharmaceutical Sciences, 1991, 80(11): 1020–1028

[24] McNeil P L, Murphy R F, Lanni F, Taylor D L. A method for incorporating macromolecules into adherent cells. The Journal of Cell Biology, 1984, 98(4): 1556–1564

[25] Chakrabarti R, Wylie D E, Schuster S M. Transfer of monoclonal antibodies into mammalian cells by electroporation. Journal of Biological Chemistry, 1989, 264(26): 15494–15500

[26] Stenmark H, Moskaug J O, Madshus I H, Sandvig K, Olsnes S. Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol. The Journal of Cell Biology, 1991, 113(5): 1025–1032

[27] Basu S K. Receptor-mediated endocytosis of macromolecular conjugates in selective drug delivery. Biochemical Pharmacology, 1990, 40(9): 1941–1946

[28] Wu G Y, Wu C H. Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro. Biochemistry, 1988, 27(3): 887–892

[29] Mellman I. Endocytosis and molecular sorting. Annual Review of Cell and Developmental Biology, 1996, 12(1): 575–625

[30] Wu A M, Yazaki P J. Designer genes: Recombinant antibody fragments for biological imaging. The Quarterly Journal of Nuclear Medicine, 2000, 44(3): 268–283

[31] Jain R K, Cook A W, Steele E L. Haemodynamic and transport barriers to the treatment of solid tumours. International Journal of Radiation Biology, 1991, 60(1–2): 85–100

[32] Juweid M, Neumann R, Paik C, Perez-Bacete M J, Sato J, van Osdol W, Weinstein J N. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Research, 1992, 52(19): 5144–5153

[33] Fawell S, Seery J, Daikh Y, Moore C, Chen L L, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91(2): 664–668

[34] Jain R K, Baxter L T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Research, 1988, 48: 7022–7032

[35] Laguzza B C, Nichols C L, Briggs S L, Cullinan G J, Johnson D A, Starling J J, Baker A L, Bumol T F, Corvalan J R. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: Design, preparation, and representative in vivo activity. Journal of Medicinal Chemistry, 1989, 32(3): 548–555

[36] Trouet A, Masquelier M, Baurain R, Campeneere D D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: In vitro and in vivo studies. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79(2): 626–629

[37] Schneck D, Butler F, Dugan W, Littrel D, Dorrbecker S. Phase I study with a murine monoclonal antibody-Vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas. Antibody Immunoconjugates Radiopharmacology, 1989, 2: 93–100

[38] Singh M, Ghose T, Kralovec J, Blair A H, Belitsky P. Inhibition of human renal cancer by monoclonal antibody-linked methotrexate in an ascites tumor model. Cancer Immunology, Immunotherapy, 1991, 32(5): 331–334

[39] Liu C, Tadayoni B M, Bourret L A, Mattocks K M, Derr S M, Widdison W C, Kedersha N L, Ariniello P D, Goldmacher V S, Lambert J M, Blattler W A, Chari R V. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93(16): 8618–8623

[40] Bader H, Ringsdorf H, Schmidt B. Watersoluble polymers in medicine. Die Angewandte Makromolekulare Chemie, 1984, 123(1): 457–485

[41] Bagshawe K D. Antibody directed enzymes revive anti-cancer prodrugs concept. British Journal of Cancer, 1987, 56(5): 531–532

[42] Duncan R. Drug-polymer conjugates: Potential for improved chemotherapy. Drug Research, 1992, 3(3): 175–210

[43] Maeda H, Seymour L W, Miyamoto Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjugate Chemistry, 1992, 3(5): 351–362

[44] Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release, 2000, 65(1-2): 271–284

[45] Seymour L W. Passive tumor targeting of soluble macromolecules and drug conjugates. Critical Reviews in Therapeutic Drug Carrier Systems, 1992, 9(2): 135–187

[46] Moreira J N, Gaspar R, Allen T M. Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochimica et Biophysica Acta, 2001, 1515(2): 167–176

[47] Kopecek J, Kopeckova P, Minko T, Lu Z R. HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50(1): 61–81

[48] Rowley G L, Rubenstein K E, Huisjen J, Ullman E F. Mechanism by which antibodies inhibit hapten-malate dehydrogenase conjugates. An enzyme immunoassay for morphine. Journal of Biological Chemistry, 1975, 250(10): 3759–3766

[49] Green M, Loewenstein P M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell, 1988, 55(6): 1179–1188

[50] Frankel A D, Pabo C O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 1988, 55(6): 1189–1193

[51] Angelastro J M, Canoll P D, Kuo J, Weicker M, Costa A, Bruce J N, Greene L A. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene, 2006, 25(6): 907–916

[52] Derossi D, Joliot A H, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. Journal of Biological Chemistry, 1994, 269(14): 10444–10450

[53] Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell, 1997, 88(2): 223–233

[54] Futaki S, Nakase I, Suzuki T, Futaki Z, Sugiura Y. Translocation of branched-chain arginine peptides through cell membranes: Flexibility in the spatial disposition of positive charges in membrane-permeable peptides. Biochemistry, 2002, 41(25): 7925–7930

[55] Park Y J, Chang L C, Liang J F, Moon C, Chung C P, Yang V C. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular low protein delivery: In vitro and in vivo study. FASEB Journal, 2005, 19(11): 1555–1557

[56] Chang L C, Lee H F, Yang Z Q, Yang V C. Low molecular weight protamine (LMWP) as nontoxic heparin/LMWH antidote (I): Preparation and characterization. AAPS PharmSci, 2001, 3(2): E17

[57] Chang L C, Liang J F, Lee H F, Lee L M, Yang V C. Low molecular weight protamine (LMWP) as nontoxic heparin/LMWH antidote (II): In vitro evaluation of efficacy and toxicity. AAPS PharmSci, 2001, 3(2): E18

[58] Lee L M, Chang L C, Wrobleski S, Wakefield T W, Yang V C. Low molecular weight protamine as nontoxic heparin/LMWH antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci, 2001, 3(2): E19

[59] Schwarze S R, Dowdy S F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends in Pharmacological Sciences, 2000, 21(2): 45–48

[60] Becker-Hapak M, McAllister S S, Dowdy S F. TAT-mediated protein transduction into mammalian cells. Methods (San Diego, Calif.), 2001, 24(3): 247–256

[61] Torchilin V P, Rammohan R, Weissig V, Levchenko T S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(15): 8786–8791

[62] Josephson L, Tung C H, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjugate Chemistry, 1999, 10(2): 186–191

[63] Schwarze S R, Ho A, Vocero-Akbani A, Dowdy S F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 1999, 285(5433): 1569–1572

[64] Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. Journal of Biological Chemistry, 2002, 277(4): 2437–2443

[65] Fawell S, Seery J, Daikh Y, Moore C, Chen L L, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91(2): 664–668

[66] Pastan I, Chaudhary V, FitzGerald D J. Recombinant toxins as novel therapeutic agents. Annual Review of Biochemistry, 1992, 61(1): 331–354

[67] Tsui B, Singh V K, Liang J F, Yang V C. Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue. Thrombosis Research, 2001, 101(5): 417–420

[68] Liang J F, Zhen L, Chang L C, Yang V C. A less toxic heparin antagonist—low molecular weight protamine. Biochemistry (Moscow), 2003, 68(1): 116–120

[69] Chertok B, David A E, Moffat B A, Yang V C. Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials, 2009, 30(35): 6780–6787

[70] Yu F, Yang V C. Size-tunable synthesis of stable superparamagnetic iron oxide nanoparticles for potential biomedical applications. Journal of Biomedical Materials Research Part A, 2010, 92(4): 1468–1475

[71] Yu F, Zhang L, Huang Y, Sun K, David A E, Yang V C. The magnetophoretic mobility and superpara-magnetism of core-shell iron oxide nanoparticles with dual targeting and imaging functionality. Biomaterials, 2010, 31(22): 5842–5848

[72] Huang Y, Park Y S, Wang J, Moon C, Kwon Y M, Chung H S, Park Y J, Yang V C. ATTEMPTS system: A macromolecular prodrug strategy for cancer drug delivery. Current Pharmaceutical Design, 2010, 16(21): 2369–2376

[73] Chertok B, David A E, Yang V C. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. Journal of Controlled Release, 2011, 155(3): 393–399

[74] Chertok B, David A E, Yang V C. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials, 2010, 31(24): 6317–6324

[75] Chertok B, David A E, Moffat B A, Yang V C. Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials, 2009, 30(35): 6780–6787

[76] Chertok B, Cole A J, David A E, Yang V C. Comparison of electron spin resonance spectroscopy and inductively-coupled plasma optical emission spectroscopy for biodistribution analysis of iron-oxide nanoparticles. Molecular Pharmaceutics, 2010, 7(2): 375–385

[77] Chertok B, David A E, Yang V C. Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials, 2011, 32(26): 6245–6253

Acknowledgements

This work was supported in part by NIH R01 Grant CA114612. This research was also partially sponsored by the National Natural Science Foundation of China (Grant No. 81361140344) and the Tianjin Municipal Science and Technology Commission (12JCZDJC34000).

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg